Patheon Contract Pharmaceutical Development Services and Commercial Manufacturing

Patheon offers its customers access to a broad range of royalty-free dosage technologies and scientific expertise.

Patheon specialises in pharmaceutical development and manufacturing services.

Active pharmaceutical ingredients (API) for the pharmaceutical sector

Patheon provides an integrated and customizable range of active pharmaceutical ingredients (API) and finished drug product services, including formulation development, clinical and commercial-scale manufacturing, packaging, and lifecycle management.

The company’s services address small and large molecule biological drugs.

Patheon is an end-to-end integrated provider, which combines scientific and regulatory expertise and specialised capabilities. This provides clients with a single outsourced provider to address complex development and manufacturing challenges.

Patheon specialises in leading product development services and commercial-scale product manufacturing.

Development and manufacturing solutions

Patheon transforms the pharmaceutical supply chain model with innovative, flexible, and customised end-to-end development, as well as manufacturing solutions that reduce complexity and shorten time-to-market.

Clients gain access to a wide range of drug substances, pharmaceutical development, and drug product solutions for large and small molecules, including an array of oral solid, sterile, and softgel dosage forms.

This provides flexibility to choose the most appropriate chemistry, manufacturing, and controls (CMC) technologies with the confidence that the programme will be delivered on time.

The company employs new business models to help clients simplify their supply chain management activities in an increasingly complex drug development industry.

Drug substance and drug product services

Patheon is organized into three distinct business units, drug substance services (DSS), pharmaceutical development services (PDS), and drug product services (DPS).

DSS is one of the top three outsourced manufacturers of highly complex biological drug substance produced in four biological API facilities. These sites are positioned to serve 70% of the market.

Patheon provides complex small molecule APIs and flexible outsourced manufacturing solutions for large molecule biologic APIs from early development through to commercial-scale production.

PDS Patheon is a leading global provider of formulation services. The company’s capabilities span the full breadth of advanced scientific services, including discovery, regulatory approval and formulation development across 40 dosage forms, as well as analytical services and life-cycle management.

DPS Patheon has developed and manufactured 20% of the top 100 drugs and 75% of the dosage forms on the market over the past decade.

Patheon has 8,700 employees, including more than 600 scientists in 25 locations in Europe, North America, Australia, and Asia.

The company has provided development and manufacturing services for approximately 400 clients for more than 700 products and molecules.

Through Patheon’s integrated global network of facilities, clients needs are met, which includes expertise to pharmaceutical, biotechnology and specialty pharmaceutical companies. This expertise helps clients bring drug candidates, including pre-clinical stages such as clinical trials and commercial supply.

Patheon provides a comprehensive suite of capabilities that addresses 75% of dosage forms with expertise and specialised capacity in high-potency, controlled substances, low-solubility, sterile, modified release, and softgel technologies.

Patheon OneSource

Patheon OneSource is an end-to-end development product that is simple to use, quick, and high-quality.

  • OneSource streamlines supply chain activities and a project manager is assigned to serve as a single point of contact for overseeing both APIs and finished products, as well as offering customers a flexible contracting process.
  • The offering can save up to 12 weeks, which is a significant improvement on the industry standard of a 15-month development cycle. In addition, Patheon can reduce redundancies through measures such as combined analytical activities, scientific collaboration, and parallel processing.
  • OneSource co-ordinates joint teams to collaborate and provide input early on in the process. Patheon has established a single harmonized quality system across its global network, ensuring it adheres to its proven track record with Right First Time and On Time Delivery, drawn on years of experience with large and small molecule APIs.

Patheon offers four specific flexible manufacturing options which are the dedicated asset model, fractional ownership model, flexible network access and the ‘condominium model.’

The company provides pharmaceutical and biotechnology companies with direct access to the expertise, quality, and full range of small or large molecule drug substance and solid and sterile dosage forms including:

  • Small molecule APIs and cGMP production
  • Process development, generic APIs and pharmaceutical intermediates portfolio
  • Biologics, mammalian cGMP and non cGMP manufacturing
  • Process and early development
  • Drug substance characterization
  • Analytical and formulation development and validation
  • Clinical trial material manufacturing
  • Late development and process and method development
  • Release and stability testing
  • Regulatory support and lifecycle management services
  • Commercial manufacturing and packaging
  • Tech transfer/scale-up management
  • Risk mitigation services

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Press Release

Patheon Has Made an Initial Public Offering of Ordinary Shares

Patheon has made an initial public offering of 30,487,805 of its ordinary shares

Product and Services
White Papers

Formulating and Producing Tablets Containing Large, Coated Multiparticulates

Controlled-release drug delivery systems can be broadly classified as either single-unit dosage forms or multiple-unit dosage forms.

Address
Patheon

US Headquarters

4721 Emperor Blvd Suite 200

Durham, NC 27703-8580

United States of America

+1 866 728 4366 +1 919 226 3200 www.patheon.com Article: Formulating and Producing Tablets Containing Large, Coated Multiparticulates

Patheon Images

White Papers

How to Choose the Right Solubilisation Technology for an API

The proportion of poorly soluble drug compounds in the development pipeline is on the rise, with 70% to 90% of current pipeline drugs falling in the two low-solubility classes of the biopharmaceutical classification system.

1 September 2016

A Cure for Pharmaceutical Supply Chain Complexity

The pharmaceutical industry lags in the sophistication and performance of its supply chains when they are compared with best-in-class companies in other industries.

2 August 2016

Bridging the Gap between Early Phase Development and Commercialisation, International Pharmaceutical Industry

The challenge of taking a drug candidate from discovery through to market should not be underestimated, as there can be many hurdles to face along the path.

24 November 2014

A Rapid Vehicle-Screening Approach for Formulating a Low-Solubility Compound into Liquid-Filled Capsules, from Tablets and Capsules

For a drug product to exert its therapeutic effect, it must be soluble in an aqueous environment. This ensures that the active pharmaceutical ingredient (API) will provide sufficient concentration to induce gastrointestinal (GI) tract absorption.

Fast and Flexible: Early Phase Manufacturing, European Biopharmaceutical Review

Early stage manufacturers of oral solid dosage forms need to be fast and flexible to generate development pathways that can cope with variable API characteristics, as well as highly potent molecules.

Formulating and Producing Tablets Containing Large, Coated Multiparticulates

Controlled-release drug delivery systems can be broadly classified as either single-unit dosage forms or multiple-unit dosage forms.

Parallel Screening, European Pharmaceutical Contractor

Improving the bioavailability of poorly soluble new chemical entities is a leading challenge in drug development. Parallel screening is a cost-effective concept for selecting a suitable drug delivery system to enhance the chance of achieving the bioavailability target in the clinic.

Formulation Strategies for Poorly Soluble Drugs

With the advent of combinatorial chemistry and high throughput screening, the number of poorly water soluble drug candidates has dramatically increased. The "drugability" of new chemical entities (NCEs) and life-cycle management of marketed pharmaceutical products are becoming more challenging.

Optimising Pharmaceutical Products Using Formulation Science, Tablets & Capsules

Approval of new drug products that treat unmet medical needs held steady or declined over the last decade.

Press Release

19 July 2016

Patheon has made an initial public offering of 30,487,805 of its ordinary shares

Read more
13 March 2016

Patheon has announced it has signed a manufacturing agreement with Amgen, one of the world's leading biotechnology companies, headquartered in Thousand Oaks, CA.

Read more
21 February 2016

Patheon has signed a strategic agreement with Grünenthal, an independent, family-owned, international research-based pharmaceutical group headquartered in Aachen, Germany, to serve as its preferred development partner for its products made using Grünenthal's innovative abuse deterrent formulation technology INTAC.

Read more
2 February 2016

The complexity of drug product supply chains has increased over the last few years mainly due to the development of more complex chemical molecules with more synthesis steps, increasing suppliers and geographies in the chain, and reduced average production volumes.

Read more
22 October 2015

Experts from Patheon will present on a range of industry topics at the 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition from 25-29 October in Orlando.

Read more
5 October 2015

Patheon will be attending the 26th Annual CPhI ICSE Worldwide conference from 13 - 15 October in Madrid.

Read more
29 September 2015

Patheon has unveiled its new brand identity, reflecting the company's leadership position in the pharmaceutical services industry, and the difference it makes in the lives of patients.

Read more
27 July 2015

LIVIA Group has entered an agreement to acquire the Capua manufacturing facility and associated employees from Patheon.

Read more
15 June 2015

Patheon has entered a development contract with Inhibrx, a biologic immunotherapeutic company focused on high, unmet medical needs in oncology, infectious disease and inflammatory conditions.

Read more
11 June 2015

Patheon will showcase ways to accelerate biologic process development and funding options for biopharmaceutical programmes at the BIO International Convention in Philadelphia from 16-17 June.

Read more
27 May 2015

Patheon has announced that Dr Marshall Crew, vice-president, global PDS scientific excellence, has been named one of the top 100 most influential people in drug development and manufacturing by the publication the Medicine Maker.

Read more
13 May 2015

Analytical development experts will address questions about regulatory requirements, stability and shipping studies in a complimentary webinar in May, sponsored by Patheon.

Read more
12 May 2015

Patheon is investing more than $3 million to expand its Greenville, North Carolina site's stability testing capabilities.

Read more
13 April 2015

Patheon will showcase its development and manufacturing services and integrated offerings at INTERPHEX in New York from Tuesday 21 to Thursday 23 April.

Read more
1 April 2015

Patheon has closed the acquisition of IRIX Pharmaceuticals, a company that specialises in making difficult to manufacture active pharmaceutical ingredients (API) for drugs from early and late development, through to commercial launch.

Read more
13 March 2015

Patheon will participate at DCAT Week 2015 in New York from 16-19 March.

Read more
9 March 2015

Patheon has reached a definitive agreement to acquire Agere Pharmaceuticals, headquartered in Bend, Oregon, that specialises in improving absorption rate of medications (bioavailability).

Read more
4 March 2015

Patheon has announced it has reached a definitive agreement to acquire IRIX Pharmaceuticals.

Read more
17 February 2015

Patheon has added a new filling technology that significantly reduces the time needed for formulation development and stability testing at its facility in Milton Park, UK.

Read more
13 February 2015

An expert from Patheon will highlight the company's strategy for delivering exceptional customer experience through its integrated offerings at the Seventh Annual Global Biomanufacturing Summit.

Read more
9 January 2015

DPx Holdings BV has announced that CEO James C Mullen will present an overview of the company and its contract development and commercial manufacturing (CDMO) business Patheon, at the 33rd Annual JP Morgan Healthcare Conference.

Read more
5 November 2014

Patheon has announced Tom Sellig will be senior-vice president of global sales and Christopher Tama will be the new senior vice-president of global marketing.

Read more
3 October 2014

Patheon is to showcase its biologic, small molecule API development services and manufacturing capabilities for finished dosage forms at CPhI / ICSE Worldwide from Tuesday 7 October to Thursday 9 October in Paris Nord Villepinte, France.

Read more
5 September 2014

Patheon is to attend a number of forthcoming pharmaceutical industry events and host informative webminars.

Read more
27 August 2014

DPx Holdings BV has announced that it has reached a definitive agreement to buy all the shares of Gallus BioPharmaceuticals, a leading contract manufacturing company specialising in biologics and current portfolio company of Ridgemont Equity Partners.

Read more
26 August 2014

Patheon, the pharmaceutical services business owned by DPx Holdings B.V, announced the launch of its updated programme Quick to Clinic™, making it the only CDMO to offer customers an accelerated 12-week clinical trial material programme with stability data, with a variety of flexible dosage forms.

Read more
19 August 2014

Patheon gives global pharmaceutical, biotechnology and specialty pharmaceutical companies access to the resources and expertise to bring drug candidates from preclinical stages through clinical trials to commercial supply.

Read more
4 August 2014

Patheon has joined with DSM Pharmaceutical Products to form businesses with an unmatched breadth of capabilities and expertise in API, biologics, development and commercial-scale manufacturing.

Read more
13 July 2014

This week, Patheon has been showcasing the company's fully integrated early development services at the 41st Annual Meeting & Exposition of the Controlled Release Society (CRS) at The Hilton Chicago in Chicago, Illinois, US.

Read more
19 June 2014

DPx Holdings BV is launching a new, US-wide operational excellence programme, called Driving Performance eXponentially (DPx).

Read more
12 June 2014

DPx Holdings BV (DPX) has donated a total of $110,000 to more than 20 hospitals and good causes around the world.

Read more
5 June 2014

Patheon has launched the SoluPath Flex™, providing the pharmaceutical industry with a new low solubility solution.

Read more
15 May 2014

Patheon is sharing a series of papers on Pharmaceutical-technology.com, targeting the early phase pharmaceutical development process.

Read more
8 May 2014

Patheon Inc is to launch the company's capabilities at FCE Pharma in Sao Paulo, Brazil, 12-14 May 2014.

Read more
3 April 2014

Patheon personnel and scientific experts will be available to meet at the CPhI/ICSE - Japan conference in Tokyo from 9-11 April to discuss how Patheon can actively support pharmaceutical and biotech companies achieve their key development and manufacturing goals.

Read more
2 April 2014

Patheon has recently received FDA approval for its Bourgoin, France site to begin manufacturing and selling drugs to the US market.

Read more
7 March 2014

Patheon is to attend the 2014 DCAT Week from 10-13 March.

Read more
22 January 2014

Patheon is to specialise in high-potency at the company's Milton Park, UK, facility. Investment in early development capabilities in Europe means increased capacity for handling highly potent compounds in the early pharmaceutical development phases in the UK and then feeding into the later stage and commercialisation capabilities at a site in Bourgoin, France.

Read more
2 December 2013

Patheon is increasing solid dose capabilities at its European sites, with the latest investments being made at its UK facility, Milton Park.

Read more
18 November 2013

JLL Partners and Royal DSM have today announced the creation of a new company, which will be a leading global contract development and manufacturing organisation (CDMO) for the pharmaceutical industry with anticipated sales of around $2bn.

Read more
22 October 2013

Patheon Inc is to attend Nuova Ompi - Stevanato Group's Innovation Day 2013 at the West Grand Frankfurt Hotel in Frankfurt, Germany, this week.

Read more
10 October 2013

Patheon will showcase its offerings, including non-sterile, sterile and softgel dose forms at CPhI/ICSE in Messe Frankfurt, Germany, 22-24 October.

Read more
5 September 2013

Patheon has released a free white paper entitled 'Formulating and Producing Tablets Containing Large, Coated Multiparticulates'.

Read more
29 August 2013

The PharmaVOICE 100 award represents a broad cross section of industry sectors.

Read more
16 July 2013

Patheon is a leading provider of contract pharmaceutical development services and commercial manufacturing. Patheon has three white papers available for download free of charge from Pharmaceutical Technology.

Read more
13 June 2013

Patheon, a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, today announced that it will be hosting a complimentary seminar entitled "Formulation, Funding and First-in-Man: A Stepwise Guide to Clinical Success".

Read more
13 June 2013

Patheon, a leading provider of contract development and manufacturing services to the global pharmaceutical industry, is hosting a complimentary, half-day seminar entitled "Product Enhancement through Complex Dosage Forms: Adding Value to Products' Lifecycle Management" on June 18, 2013 at the MassBio Headquarters in Cambridge, Massachusetts.

Read more
22 April 2013

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that the company will showcase its high potency capabilities at the 2013 BIO International Convention in Chicago, Illinois on April 22 - 25, 2013, as well as at INTERPHEX 2013 in New York City on April 23 - 25, 2013.

Read more
22 April 2013

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, will be exhibiting and presenting at the 2013 Global Formulation and Drug Delivery Summit in Amsterdam, the Netherlands.

Read more
7 March 2013

Internationally renowned pharmaceutical contract developer Patheon has released a preview of its online seminar, entitled 'Getting Your Drug through Phase I Early Development Effectively', on Pharmaceutical Technology.

Read more
6 March 2013

Patheon, a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, today announced plans for additional investment in its Milton Park facility.

Read more
17 December 2012

Patheon, a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results for fiscal 2012.

Read more
17 December 2012

Patheon, a leading provider of contract development and manufacturing services to the global pharmaceutical industry, today announced that it has completed its acquisition of Banner Pharmacaps (Banner), a specialty pharmaceutical business dedicated to the research, development and manufacturing of unique gelatin-based dosage forms.

Read more

Regional Offices

Patheon

US Headquarters

4721 Emperor Blvd Suite 200

Durham, NC 27703-8580

United States of America

+1 866 728 4366 +1 919 226 3200 www.patheon.com Article: Formulating and Producing Tablets Containing Large, Coated Multiparticulates
Patheon UK Limited European Headquarters and Swindon Operations (SND)

Kingfisher Drive

Covingham, Swindon

Wiltshire SN3 5BZ

United Kingdom

+44 1793 524411 +44 1793 487053 Full list of regional offices
Patheon K.K. Japan Office

7F Wakamatsu Building, 3-3-6

Nihonbashi Hon-cho, Chuo-ku,

Tokyo 103-0023

Japan

+81 3 6202 7666 +81 3 6202 7676 Full list of regional offices

Contact company

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.